(KROS) Keros Therapeutics - Ratings and Ratios
Therapeutics, Clinical, Hematology, Cardiovascular, Neuromuscular
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 77.9% |
| Value at Risk 5%th | 110% |
| Relative Tail Risk | -14.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.52 |
| Alpha | -72.67 |
| CAGR/Max DD | -0.28 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.556 |
| Beta | 0.307 |
| Beta Downside | -0.710 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.45% |
| Mean DD | 42.61% |
| Median DD | 35.05% |
Description: KROS Keros Therapeutics October 23, 2025
Keros Therapeutics (NASDAQ: KROS) is a clinical-stage biopharma focused on diseases driven by dysregulated transforming growth factor-beta (TGF-β) signaling, targeting U.S. patients with unmet needs in hematology, pulmonary vascular, and neuromuscular disorders.
The lead candidate, KER-050, is in late-stage trials for cytopenias associated with myelodysplastic syndromes (MDS) and myelofibrosis, while KER-012 is in Phase II for pulmonary arterial hypertension (PAH) and related cardiovascular conditions, and KER-065 is in Phase I for neuromuscular diseases. A licensing partnership with Hansoh Healthtech grants Keros rights to develop and commercialize elritercept in China, potentially unlocking a large, rapidly growing market for TGF-β modulators.
As of the latest Q2 2024 filing, Keros held roughly $120 million in cash and marketable securities, supporting a projected cash runway of about 12 months at its current burn rate of $30 million per year; the company’s market cap hovers near $300 million, placing it in the lower-mid range of biotech valuations. The global TGF-β therapeutic market is estimated to reach $5 billion by 2028 (≈12 % CAGR), and overall biotech R&D spending is up ~8 % YoY, underscoring a favorable macro environment for innovative pipeline players.
For a deeper, data-driven look at KROS’s valuation and risk profile, the analyst commentary on ValueRay can provide useful context.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (64.4m TTM) > 0 and > 6% of Revenue (6% = 14.8m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 36.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 281.8% (prev 80.3k%; Δ -80.1kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 88.8m > Net Income 64.4m (YES >=105%, WARN >=100%) |
| Net Debt (-676.0m) to EBITDA (82.4m) ratio: -8.21 <= 3.0 (WARN <= 3.5) |
| Current Ratio 29.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (40.6m) change vs 12m ago 12.52% (target <= -2.0% for YES) |
| Gross Margin 99.42% (prev -75.73%; Δ 175.1pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 37.32% (prev 0.11%; Δ 37.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.26 (EBITDA TTM 82.4m / Interest Expense TTM 9.80m) >= 6 (WARN >= 3) |
Altman Z'' -7.32
| (A) 0.94 = (Total Current Assets 719.3m - Total Current Liabilities 24.1m) / Total Assets 742.8m |
| (B) -0.62 = Retained Earnings (Balance) -458.3m / Total Assets 742.8m |
| (C) 0.12 = EBIT TTM 80.9m / Avg Total Assets 661.0m |
| (D) -11.69 = Book Value of Equity -458.3m / Total Liabilities 39.2m |
| Total Rating: -7.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.67
| 1. Piotroski 6.50pt |
| 2. FCF Yield -55.18% |
| 3. FCF Margin 35.30% |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda -8.21 |
| 6. ROIC - WACC (= 3.07)% |
| 7. RoE 9.51% |
| 8. Rev. Trend 46.49% |
| 9. EPS Trend 30.96% |
What is the price of KROS shares?
Over the past week, the price has changed by +24.08%, over one month by +38.59%, over three months by +39.13% and over the past year by -66.43%.
Is KROS a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the KROS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.3 | 7.2% |
| Analysts Target Price | 23.3 | 7.2% |
| ValueRay Target Price | 20.6 | -5% |
KROS Fundamental Data Overview November 26, 2025
P/E Trailing = 10.9038
P/E Forward = 48.7805
P/S = 2.1005
P/B = 0.753
Beta = 0.912
Revenue TTM = 246.7m USD
EBIT TTM = 80.9m USD
EBITDA TTM = 82.4m USD
Long Term Debt = 17.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.32m USD (from shortTermDebt, last quarter)
Debt = 17.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -676.0m USD (from netDebt column, last quarter)
Enterprise Value = -157.8m USD (518.2m + Debt 17.4m - CCE 693.5m)
Interest Coverage Ratio = 8.26 (Ebit TTM 80.9m / Interest Expense TTM 9.80m)
FCF Yield = -55.18% (FCF TTM 87.1m / Enterprise Value -157.8m)
FCF Margin = 35.30% (FCF TTM 87.1m / Revenue TTM 246.7m)
Net Margin = 26.12% (Net Income TTM 64.4m / Revenue TTM 246.7m)
Gross Margin = 99.42% ((Revenue TTM 246.7m - Cost of Revenue TTM 1.44m) / Revenue TTM)
Gross Margin QoQ = 97.23% (prev 97.96%)
Tobins Q-Ratio = -0.21 (set to none) (Enterprise Value -157.8m / Total Assets 742.8m)
Interest Expense / Debt = 56.22% (Interest Expense 9.80m / Debt 17.4m)
Taxrate = 16.36% (-1.42m / -8.70m)
NOPAT = 67.7m (EBIT 80.9m * (1 - 16.36%))
Current Ratio = 29.86 (Total Current Assets 719.3m / Total Current Liabilities 24.1m)
Debt / Equity = 0.02 (Debt 17.4m / totalStockholderEquity, last quarter 703.6m)
Debt / EBITDA = -8.21 (Net Debt -676.0m / EBITDA 82.4m)
Debt / FCF = -7.76 (Net Debt -676.0m / FCF TTM 87.1m)
Total Stockholder Equity = 677.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.68% (Net Income 64.4m / Total Assets 742.8m)
RoE = 9.51% (Net Income TTM 64.4m / Total Stockholder Equity 677.7m)
RoCE = 11.64% (EBIT 80.9m / Capital Employed (Equity 677.7m + L.T.Debt 17.4m))
RoIC = 9.99% (NOPAT 67.7m / Invested Capital 677.7m)
WACC = 6.92% (E(518.2m)/V(535.7m) * Re(7.15%) + (debt cost/tax rate unavailable))
Discount Rate = 7.15% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 16.12%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈87.1m ; Y1≈107.4m ; Y5≈183.3m
Fair Price DCF = 102.3 (DCF Value 3.12b / Shares Outstanding 30.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 30.96 | EPS CAGR: 2.52% | SUE: 0.63 | # QB: 0
Revenue Correlation: 46.49 | Revenue CAGR: -8.62% | SUE: 0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.58 | Chg30d=+0.817 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.07 | Chg30d=+0.947 | Revisions Net=+2 | Growth EPS=-230.4% | Growth Revenue=-91.8%
Additional Sources for KROS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle